Synaptogenix announces peer-reviewed publication of nih-sponsored phase 2 clinical trial results demonstrating safe, significant, and persistent benefits of bryostatin-1 in advanced alzheimer's disease

Bryostatin-1 benefits in severe alzheimer's disease patients were statistically significant with respect to placebo at p < 0.007 new york , sept. 26, 2023 /prnewswire/ -- synaptogenix, inc. (nasdaq: snpx) ("synaptogenix" or the "company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced a peer-reviewed publication of statistically significant integration of secondary and exploratory endpoint data from its previously completed phase 2 trial of bryostatin-1 for alzheimer's disease.
SNPX Ratings Summary
SNPX Quant Ranking